Business Description

ITeos Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US46565G1040
Description
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 109.99 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.09 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 4.74 | |||||
Beneish M-Score | 13.19 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year FCF Growth Rate | -7.2 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 40.5 | |||||
9-Day RSI | 44.44 | |||||
14-Day RSI | 45.52 | |||||
6-1 Month Momentum % | -15.37 | |||||
12-1 Month Momentum % | -41.04 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 20.47 | |||||
Quick Ratio | 20.47 | |||||
Cash Ratio | 19.96 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.9 | |||||
Shareholder Yield % | -0.05 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -70.98 | |||||
Net Margin % | -33.04 | |||||
ROE % | -4.42 | |||||
ROA % | -3.76 | |||||
ROIC % | -61.9 | |||||
ROC (Joel Greenblatt) % | -869.16 | |||||
ROCE % | -8.81 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 5.35 | |||||
PB Ratio | 0.69 | |||||
Price-to-Tangible-Book | 0.69 | |||||
EV-to-EBIT | 2.55 | |||||
EV-to-EBITDA | 2.59 | |||||
EV-to-Revenue | -1.81 | |||||
EV-to-Forward-Revenue | 3.81 | |||||
EV-to-FCF | 1.28 | |||||
Price-to-Net-Current-Asset-Value | 0.81 | |||||
Price-to-Net-Cash | 0.83 | |||||
Earnings Yield (Greenblatt) % | 39.22 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ITOS
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ITeos Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 85.987 | ||
EPS (TTM) ($) | -0.82 | ||
Beta | 0.93 | ||
Volatility % | 43.88 | ||
14-Day RSI | 45.52 | ||
14-Day ATR ($) | 0.657545 | ||
20-Day SMA ($) | 12.57925 | ||
12-1 Month Momentum % | -41.04 | ||
52-Week Range ($) | 11.34 - 23 | ||
Shares Outstanding (Mil) | 35.78 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
ITeos Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
ITeos Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
ITeos Therapeutics Inc Frequently Asked Questions
What is ITeos Therapeutics Inc(ITOS)'s stock price today?
The current price of ITOS is $12.07. The 52 week high of ITOS is $23.00 and 52 week low is $11.34.
When is next earnings date of ITeos Therapeutics Inc(ITOS)?
The next earnings date of ITeos Therapeutics Inc(ITOS) is 2023-11-10 Est..
Does ITeos Therapeutics Inc(ITOS) pay dividends? If so, how much?
ITeos Therapeutics Inc(ITOS) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |